EVH (Evolent Health) ROCE %: -2.35% (As of Mar. 2026)

What is Evolent Health ROCE %?

Evolent Health EVH +4.79% 60 ROCE % is -2.35% as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 60/100 and a GF Value™ of $11.05 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Evolent Health's annualized ROCE % for the quarter that ended in Mar. 2026 was -2.35%.

Evolent Health (NYSE:EVH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Evolent Health ROCE % Related Terms

Evolent Health ROCE % Historical Data

* Premium members only.

The historical data trend for Evolent Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health ROCE % Chart

Evolent Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-0.45

-3.94

-8.74

-2.00

-28.55

Evolent Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-11.28	-2.17	-1.19	-92.05	-2.35

60GF Score

Evolent Health Inc EVH

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evolent Health ROCE % Calculation

Evolent Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-477.165	/	( ( (2544.411 - 715.501)	+	(1899.236 - 385.26) )	/ 2 )
	=	-477.165	/	( (1828.91	+	1513.976)	/ 2 )
	=	-477.165	/	1671.443
	=	-28.55 %

Evolent Health's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-35.416	/	( ( (1899.236 - 385.26)	+	(1878.847 - 381.235) )	/ 2 )
	=	-35.416	/	( ( 1513.976	+	1497.612 )	/ 2 )
	=	-35.416	/	1505.794
	=	-2.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -2.35% mean?

Evolent Health (EVH) has a ROCE % of -2.35% as of Mar. 2026.

Is Evolent Health's ROCE % too high?

Evolent Health's current ROCE % is -2.35%. Overall, Evolent Health has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Evolent Health's ROCE % compare to NRC and CTEV?

Evolent Health's ROCE % of -2.35% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current ROCE % is -2.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evolent Health stock overvalued right now?

Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.05, compared to a current price of $5.03 — trading 54.5% below its estimated fair value. The current ROCE % is -2.35%. Evolent Health's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Evolent Health (EVH), the current ROCE % is -2.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (EVH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of $5.03 is trading 54.5% below its estimated GF Value™ of $11.05. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for EVH:

ROCE %: -2.35%
GF Value™: $11.05 vs. price of $5.03 (54.5% below fair value)
GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolent Health Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies NRC CTEV WEAV TBRG SOPH SLP CARL PHR SPOK LFMD VEEV BTSG ASX:PME TEM HQY TSE:2413 HKSE:02228 HNGE DOCS WAY

Other Exchanges 9EH:Germany

Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209

Website https://www.evolenthealth.com

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

60GF Score

Get the complete analysis for EVH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.03

Price

$11.05

GF Value

View EVH Analysis

See ROCE % data for all stocks →